Effects of enteral glutamine on gut mucosal protein synthesis in healthy humans receiving glucocorticoids.
In hypercatabolic patients, the beneficial effects of glutamine on gut mucosa could be partly due to a stimulation of protein synthesis. The fractional synthesis rate (FSR) of gut mucosal protein was measured in four groups of healthy volunteers treated with glucocorticoids for 2 days. Two groups were studied in the postabsorptive state while receiving glutamine or a nitrogen equivalent (control) and two groups in the fed state with or without glutamine, using a 5-h intravenous infusion of [(13)C]leucine, [(2)H(5)]phenylalanine, and cortisone. After nutrient and tracer infusion, duodenal biopsies were taken. In the postabsorptive state, FSR of gut mucosal protein were 87 and 76%/day in the control group and 130% (P = 0.058 vs. control) and 104% (P = 0.17 vs. control)/day in the glutamine group, with leucine and phenylalanine as tracers, respectively. During feeding, FSR did not increase and no significant difference was observed between glutamine and control groups. Overall, FSR of the four groups were two- to threefold higher than those obtained previously in healthy humans, suggesting that glucocorticoids may increase gut mucosal protein synthesis. However, in this situation, a moderate enteral glutamine supply failed to demonstrate a significant effect on gut mucosal protein synthesis in the postabsorptive state and during feeding.
Bouteloup-Demange
C
C
Groupe de Biochimie et Physiopathologie Digestive Nutritionnelle and Institut Fédératif de Recherche Multidisciplinaire sur les Peptides No. 23, Faculté de Médecine-Pharmacie, 76183 Rouen Cedex, France.
Claeyssens
S
S
Maillot
C
C
Lavoinne
A
A
Lerebours
E
E
Dechelotte
P
P
D000284:Administration, Oral; D000328:Adult; D002247:Carbon Isotopes; D004386:Duodenum; D004750:Enteral Nutrition; D005260:Female; D005938:Glucocorticoids / Q000494:pharmacology*; D005973:Glutamine / Q000008:administration & dosage / Q000494:pharmacology*; D006801:Humans; D007262:Infusions, Intravenous; D007408:Intestinal Absorption; D007413:Intestinal Mucosa / Q000187:drug effects / Q000378:metabolism*; D007651:Keto Acids / Q000378:metabolism; D007930:Leucine / Q000008:administration & dosage / Q000378:metabolism; D008297:Male; D010649:Phenylalanine / Q000008:administration & dosage / Q000378:metabolism; D011239:Prednisolone / Q000008:administration & dosage / Q000494:pharmacology*; D014176:Protein Biosynthesis; D014316:Tritium
D002247:Carbon Isotopes; D005938:Glucocorticoids; D007651:Keto Acids; D005973:Glutamine; D014316:Tritium; D010649:Phenylalanine; C013082:alpha-ketoisocaproic acid; D011239:Prednisolone; D007930:Leucine